CONTEXT: Yet another announcement of a venture capital funded company focused on commercialising real-world data sources | Are we opening up sources or slamming the door shut unless you have enough money? Time will tell…
IMPACT: Low
READ TIME: 2 min
Quality Level Mean [1 – 10]: 2
1. “Alongside raising $220 million in new venture capital, digital healthcare mapmaker Komodo Health has charted a partnership with Johnson & Johnson’s pharmaceutical wing, Janssen Research & Development, to help provide real-world data and artificial intelligence-powered analysis.”
2. “Komodo’s database traces the healthcare journeys of more than 325 million patients as they receive tests, undergo treatments and respond to therapies to provide a large, anonymized resource for biopharma research.”
3. “This month Janssen relied on real-world data to help make the case for its Uptravi (selexipag) therapy for pulmonary arterial hypertension, showing that about three-quarters of treated patients maintained or reduced their risk assessment scores despite the progressive disease.”
4. “Meanwhile, Komodo signed an acquisition deal earlier this year for Mavens, a cloud software developer for specialty biotech and pharma companies, as well as a multi-year data sharing agreement with Blue Health Intelligence, to integrate the latter’s longitudinal dataset of commercial medical and pharmacy claims culled from insurers, universities and other sources.”
5. ““As long-time investors in the intersection of life sciences and next-generation technologies, it was quickly clear to us the scale advantage and impact potential of Komodo Health,” Eli Casdin, founder of Casdin Capital, said in a statement.”
Source URL: https://www.fiercebiotech.com/medtech/komodo-health-charts-out-220m-round-janssen-real-world-data-deal